Beyond Air (XAIR)
(Delayed Data from NSDQ)
$1.28 USD
+0.05 (4.07%)
Updated May 31, 2024 04:00 PM ET
After-Market: $1.26 -0.02 (-1.56%) 7:58 PM ET
2-Buy of 5 2
F Value D Growth F Momentum F VGM
Brokerage Reports
0 items in cart
Beyond Air, Inc. [XAIR]
Reports for Purchase
Showing records 21 - 40 ( 54 total )
Company: Beyond Air, Inc.
Industry: Medical - Drugs
Company: Beyond Air, Inc.
Industry: Medical - Drugs
Reasons to Sit Down with These Healthcare/Biotech Management
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: Beyond Air, Inc.
Industry: Medical - Drugs
Company: Beyond Air, Inc.
Industry: Medical - Drugs
Company: Beyond Air, Inc.
Industry: Medical - Drugs
Company: Beyond Air, Inc.
Industry: Medical - Drugs
Company: Beyond Air, Inc.
Industry: Medical - Drugs
Company: Beyond Air, Inc.
Industry: Medical - Drugs
Company: Beyond Air, Inc.
Industry: Medical - Drugs
Company: Beyond Air, Inc.
Industry: Medical - Drugs
FY1Q22 Recap - LungFit PH Approval Targeted for Late Sept
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Beyond Air, Inc.
Industry: Medical - Drugs
Company: Beyond Air, Inc.
Industry: Medical - Drugs
Company: Beyond Air, Inc.
Industry: Medical - Drugs
Company: Beyond Air, Inc.
Industry: Medical - Drugs
FY3Q21 Recap - Programs on Track for Mid CY2021 Catalysts
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S
Company: Beyond Air, Inc.
Industry: Medical - Drugs
Company: Beyond Air, Inc.
Industry: Medical - Drugs
Company: Beyond Air, Inc.
Industry: Medical - Drugs
FY2Q21 Recap - Filing Complete; New Trials on Tap
Provider: Roth Capital Partners, Inc.
Analyst: HENRY S